Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olaparib monotherapy in previously treated HRR-mutated or HRD-positive advanced cancer
2022-500797-34-00Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Feb 2023
- Modality
- Small Molecules
- Countries
- 21
01
Overview
Phase 2, open-label, single-arm trial of olaparib in advanced nonhematological malignancy, breast cancer, ovarian cancer and 1 more, sponsored by Merck & Co. Primary endpoint: Objective Response Rate (ORR). Started Feb 2023; status: completed.
02
Drugs
olaparib
03
Conditions
advanced nonhematological malignancybreast cancerovarian cancerprostate cancer (PCa)
Beyond the preview
Go deeper on 2022-500797-34-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-500797-34-00.